Mirum Pharmaceuticals price target raised to $66 from $48 at Stifel

Stifel raised the firm’s price target on Mirum Pharmaceuticals to $66 from $48 and keeps a Buy rating on the shares. The recent interim analyses from Phase 2b VISTAS study in primary sclerosing cholangitis and VANTAGE study in primary biliary cholangitis were better than expected, and Stifel is incrementally more optimistic about PBC vs. PSC at this juncture, the analyst tells investors in a research note. The firm raised its PoS to 55% for PBC and 40% for PSC from 20% for both, previously.